Mylan acquires two dermatological products from Valeant
Mylan has completed the acquisition of two dermatological treatments from Valeant Pharmaceuticals.
Mylan might have recently used a negotiation consultancy, as the drugs company has completed the acquisition from Valeant Pharmaceuticals of two dermatological products.
It has secured a licence to market and manufacture Fluorouracil 5 per cent USP cream, which is used for solar or multiple actinic keratosis, as well as for superficial basal cell carcinomas when more conventional tools have been deemed impractical.
Furthermore, it has acquired the abbreviated new drug application for Benzoyl Peroxide Gel / Clindamycin Phosphate, which is utilised to treat acne vulgaris and had sales of around $205 million (£129.61 million) during 2011.
"The acquisition of these two products reflects Mylan's continued strategy of creating value through increasing our position in key therapeutic areas and dosage forms, such as dermatological topicals," chief executive officer of the company Heather Bresch said.
Valeant Pharmaceuticals specialises in the development, advertisement and manufacture of drugs, specifically within the areas of branded generics, neurology and dermatology.
Posted by Ron Maverick
Source: Mylan press release, February 6th